An MRD-guided strategy incorporating teclistamab-daratumumab intensification produced deep responses in newly diagnosed high-risk multiple myeloma, although infections affected more than three-fourths of treated patients.
|Articles|August 19, 2022
Daily Medication Pearl: Kcentra [Prothrombin Complex Concentrate (Human)]
Author(s)Saro Arakelians, PharmD
Kcentra is indicated for the urgent reversal of acquired coagulation factor deficiency induced by vitamin K antagonist therapy in adult patients with acute major bleeding.
Advertisement
Medication Pearl of the Day: Kcentra [Prothrombin Complex Concentrate (Human)]
Indication: Kcentra [prothrombin complex concentrate (human)], is indicated for the urgent reversal of acquired coagulation factor deficiency induced by vitamin K antagonist (e.g., warfarin) therapy in adult patients with acute major bleeding.
Insight:
- Dosing: 20 to 50 units/kg, do not exceed 2500 to 5000 units.
- Dosage forms: Kcentra is available as a single-use vial containing coagulation factors II, VII, IX and X, and antithrombotic proteins C and S as a lyophilized concentrate.
- Adverse events: The most common adverse reactions (frequency ≥2.8%) observed in subjects receiving Kcentra were headache, nausea/vomiting, arthralgia, and hypotension.
- Mechanism of action: Kcentra contains the vitamin K-dependent coagulation factors II (FII), VII (FVII), IX (FIX), and X (FX), together known as the prothrombin complex, and the antithrombotic protein C and protein S. If the patient has an acquired coagulation factor deficiency where one or more of the vitamin K-dependent coagulation factors are deficient, bleeding may occur.
Advertisement
Related to this article
Phase 2 MILESTONE results suggest that postinduction minimal residual disease (MRD) negativity can identify a small subset of transplant-eligible patients with newly diagnosed multiple myeloma who may defer autologous stem cell transplantation.
Fixed-duration KRd slowed progression in high-risk smoldering myeloma, but high rates of severe toxicity temper enthusiasm.
September’s pain management coverage examined postoperative nonopioid options, lessons from sickle cell pain research, and pharmacists’ experiences with controlled-substance prescribing.
September’s hematology coverage examined a new definition of myeloma cure, patient preferences for treatment delivery, and emerging strategies for deepening responses.
FDA clears tiratricol for MCT8 deficiency, lowering dangerous T3 and outlining dosing, lab testing, and pharmacy access.
A single infusion reversed new-onset type 1 diabetes (T1D) in more than half of treated mice by strengthening regulatory T cells and driving autoreactive CD8+ T cells into a less destructive state.
A detailed LINKER-MM1 analysis found that cytokine release syndrome (CRS) with linvoseltamab occurred early, was predominantly low grade, and became less frequent with successive step-up and full doses.
Advertisement
Advertisement
Trending on Pharmacy Times
1
What the 2025-2030 Dietary Guidelines Mean for Heart Health
2
Why Lp(a) Testing Lagged Behind LDL Cholesterol Screening
3
EloraTZP Delivers Up to 23.3% Weight Loss in Adults With Obesity and T2D
4
FDA Approves Pirtobrutinib for Previously Untreated CLL/SLL
5